Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 13/20 | 0.58 |
| ▸ | IL2 | P60568 | 6/20 | 0.58 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 4/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21592937 | 0.92 | MAP4K1 (0.56) | MAP4K1IL2TNIKKITCAMKK2 | |
| SCHEMBL21592622 | 0.92 | MAP4K1 (0.59) | MAP4K1IL2TNIKPIK3CGCAMKK2 | |
| SCHEMBL21592893 | 0.87 | MAP4K1 (0.57) | MAP4K1TNIKCAMKK2 | |
| SCHEMBL21592631 | 0.87 | MAP4K1 (0.57) | MAP4K1IL2TNIKPIK3CGCAMKK2 | |
| SCHEMBL21592757 | 0.87 | MAP4K1 (0.54) | MAP4K1IL2TNIKPIK3CGCAMKK2 | |
| SCHEMBL21593056 | 0.87 | MAP4K1 (0.58) | MAP4K1IL2TNIKPIK3CGCAMKK2 | |
| SCHEMBL21592647 | 0.86 | MAP4K1 (0.62) | MAP4K1IL2TNIKCAMKK2 | |
| SCHEMBL21592637 | 0.85 | MAP4K1 (0.59) | MAP4K1IL2TNIKKITDYRK1A | |
| SCHEMBL21592870 | 0.85 | MAP4K1 (0.59) | MAP4K1IL2TNIKKITDYRK1A | |
| SCHEMBL21592889 | 0.85 | MAP4K1 (0.57) | MAP4K1IL2TNIKDYRK1ACAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019238067-A1 | PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2019-12-19 | — | — | WO | disclosed |